Clients covered by government programs need not apply
By Mari Serebrov Regulatory Editor When Mylan NV aimed to put out the general public outcry over its newest hike in the Epipen cost by expanding its client assistance programs (PAPs), U.S. lawmakers weren’t impressed. “PAPs appear like a playbook all [drug] companies are utilizing rather of coming down on the rate,” Rep. Elijah Cummings (D-Md.) respo …
See all stories on this subject
